Maurer, M and P Kaplan, A and Elieh Ali Kom, D and A Khan, D (2021) Biologics for the Use in Chronic Spontaneous Urticaria: When and Which. J Allergy Clin Immunol Pract, 9. pp. 1067-1078.
|
Text
2235.pdf Download (2MB) | Preview |
Abstract
Guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend the use of the IgE-targeted biologic omalizumab in patients with antihistamine-refractory disease. The rationale for this is supported by the key role of IgE and its high-affinity receptor, FcεRI, in the degranulation of skin mast cells that drives the development of the signs and symptoms of CSU, itchy wheals, and angioedema. Here, we review the current understanding of the pathogenesis of CSU and its autoimmune endotypes. We describe the mechanisms of action of omalizumab, the only biologic currently approved for CSU, its efficacy and ways to improve it, biomarkers for treatment response, and strategies for its discontinuation. We provide information on the effects of the off-label use, in CSU, of biologics licensed for the treatment of other diseases, including
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Chronic spontaneous urticaria; Angioedema; Eosinophils; Basophils; Antihistamine; Novel biologics; Anti-IgE receptor; Mast cells; Omalizumab |
| Subjects: | R Medicine > R Medicine (General) |
| Depositing User: | Unnamed user with email gholipour.s@umsu.ac.ir |
| Date Deposited: | 07 Jun 2021 04:12 |
| Last Modified: | 07 Jun 2021 04:12 |
| URI: | http://eprints.umsu.ac.ir/id/eprint/6234 |
Actions (login required)
 |
View Item |
